‘What about the Kingsford Smith Cup horses?': Trainer Joe Pride disappointed Group 1 not rescheduled to Wednesday
Trainer Joe Pride admitted he was 'disappointed' the Group 1 Kingsford Smith Cup wasn't rescheduled for midweek before ruling his elite sprinter out of the $1 million Eagle Farm race on Saturday.
The Kingsford Smith Cup and Queensland Derby were added to the Oaks Day program at Eagle Farm after heavy rain last Saturday resulted in the final five races being washed out.
But Pride questioned why only the Group 3 Fred Best Classic was moved to the Doomben meeting on Wednesday and not the Kingsford Smith Cup, too.
Pride said Private Eye 's preparation would be compromised if the gelding ran first-up in Saturday's Kingsford Smith Cup and then the Group 1 $3 million Stradbroke Handicap (1400m) at Eagle Farm on June 14.
'I'm not going to run Private Eye in the Kingsford Smith Cup and then back up a week later in the Stradbroke Handicap,'' Pride said.
'I don't want to give him a compromised preparation and have a half-hearted go at two Group 1 races.
'I'm disappointed he has to miss the Kingsford Smith Cup but this way we can give him his best chance in the Stradbroke.''
Pride revealed Private Eye returned to Sydney over the weekend as the gelding preferred his training and stable routine at Warwick Farm.
'We will trial Private Eye on Friday at Rosehill and that will give him four barrier trials before his first-up run so I'm not worried about his fitness,'' Pride said.
Private Eye will bypass the Kingsford Smith @EagleFarmRacing this Saturday to concentrate on the Stradbroke with @nashhot on board @ProvenTbreds star is in great shape and will trial this Friday
— Pride Racing (@PrideRacing) June 1, 2025
'But I feel they could have run the Kingsford Smith Cup on Wednesday. They have added the Fred Best Classic to the Doomben meeting to give the three-year-olds their best chance of getting to the Stradbroke.
'But that is only for one horse (Fred Best Classic winner) so what about all the Kingsford Smith Cup horses?'
Joliestar 's owner Brendan Lindsay has already suggested his brilliant mare was likely to go for a spell after the Kingsford Smith Cup and not stay in training for the Stradbroke.
This is more to do with giving Joliestar a long enough break before the spring carnival comes around rather than having to race her twice in seven days.
'I think she's 50-50 for the 'Straddie', I don't think she'll carry on,'' Lindsay said
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
an hour ago
- West Australian
Geraldton netball star Allen Greichen to don the green and gold
Geraldton netball star Allen Griechen has been selected in the Australia squad to play against New Zealand in Melbourne later this year. Allen has shone bright on the court catching the attention of selectors along with way as he continues to build an impressive athletic CV. Beginning his netball journey at seven years of age, it wasn't long before Allen was playing in a representative side — in 2023 he was selected for the inaugural State school boys under-12 team. After an impressive outing for the under-12 team, Allen then went on to trial for the West Coast Thunder under-17s. With low expectations due to his age, Allen surprised himself when he was selected in September last year to join the squad. Allen has had to endure a rigorous training and playing routine, travelling to Perth most weekends competing from early October last year to April. Finding himself in a new position in goal keeper, Allen's mum Robyn said he impressed with how well he took to the new situation. 'Allen had an amazing tournament,' she said. 'He has really taken to the GK position, which was a new role for him in netball. 'The coaches saw something in him for that position, and he has enjoyed developing that part of his game. 'Obviously, we are ecstatic for him, and proud of him.' The 14-year-old then travelled to Sydney in May to take part in a three-day camp from which he was selected to represent Australia in July against New Zealand in the International Test Series. He persevered in the camp and impressed selectors and was amongst the 15 boys selected to compete for Australia in the 17 and under 2025 series. Allen will fly to New Zealand in July to don the green and gold in what will be his biggest achievement as an athlete to date.
The Australian
3 hours ago
- The Australian
New treatment allows cancer patients to avoid going under the knife
You can now listen to The Australian's articles. Give us your feedback. You can now listen to The Australian's articles. Australian hospitals have adopted a new combination chemotherapy for bladder cancer that has brought remission rates to 60 per cent, taking patients out from under the knife. A blend of the drugs Gemcitabine and Docetaxel has seen patients sidestep side effects while cutting rates of surgical bladder removal since being trialled at Monash Health in 2023, with the treatment now available to hospitals. Hailed as a means to 'change the whole protocol for the treatment of bladder cancer', the combination takes medications already made affordable by the Pharmaceutical Benefits Scheme to an eligible population of thousands of patients. The drugs are referred to collectively as Gem-Doce. It represents the first non-surgical alternative in bladder cancer treatment since the decades-old introduction of tuberculosis drug Bacillus Calmette-Guerin, for which supply is volatile. Retired teacher Alan Feher, 72, was a successful recipient of the combination therapy after he was diagnosed with aggressive bladder cancer. He had been late to catch his cancer, given he is colour blind and missed the most obvious symptom of blood in his urine. He was also misdiagnosed with an enlarged prostate in 2018 before landing on the true cause of his symptoms. 'It's quite by accident that the process started because I was mainly concerned about prostate cancer, and didn't have much idea about bladder cancer,' he said. 'The biopsy showed two things: that it was a non-invasive bladder cancer, and it was also high grade. 'The urologist said it was normal to remove the bladder and the prostate … that's looking at quite radical surgery, which would have meant having some kind of a bag hanging off of my body, where the kidneys redirected outside of my body … I nearly fainted when I heard that.' Facing the prospect of surgery, his entrance into the 2023 drug trial led him into remission. Urological Society of Australia and New Zealand president Damien Bolton welcomed the successful combination therapy, pointing to rising death rates from bladder cancer as an indication of how necessary new treatments were. Its lethality has risen in line with Australia's ageing population. Weranja Ranasinghe. Picture: Monash Health Urological Society of Australia and New Zealand president Damien Bolton. 'One way we can hold back and hopefully cure bladder cancer is not by having a big operation to remove your bladder and give you a stoma, or by having chemotherapy and radiation which have serious toxicities, but by putting different anti-cancer agents into the bladder, and this combination … Gem-Doce, is a huge step forward for that,' he said. 'Since the time of Covid, there's been a shortage worldwide of BCG … in Australia, like many countries around the world, we've had to ration our use. 'Now with Gem-Doce, you've got the ability to reserve BCG for when it's most needed, and you've got another viable alternative.' Professor Bolton said he hoped, pending the therapy's success, it would be adopted into recommended treatment guidelines. Annually, more than 3000 Australians are diagnosed with bladder cancer, most aged over 50. An aggressive cancer, it disproportionately affects men. In isolation, Gemcitabine and Docetaxel are poor treatments for bladder cancer; when administered together, 60-69 per cent of patients respond positively. A simultaneous European study has reported a 79 per cent high-grade disease-free survival rate and 73 per cent overall disease-free survival rate. Monash Health study lead Weranja Ranasinghe said the therapy would take patients out of palliative care. 'This new treatment provides an excellent alternative for these patients with good tolerance and durability. The other advantage is that these agents are widely available and affordable,' Associate Professor Ranasinghe said. 'The new treatment, Gem-Doce, is (using) established chemotherapy medicines and administering them sequentially into the bladder is shown to be effective in about 60 to 69 per cent of patients who don't respond to BCG treatment or who want to preserve their bladder.' Read related topics: HealthVaccinations
News.com.au
6 hours ago
- News.com.au
‘Unusual' thing happening to the Aussie dollar in wake of Trump tariffs, says Reserve Bank
The global uncertainty sparked by US President Donald Trump's tariff agenda has resulted in something unusual happening to the Australian dollar. RBA assistant governor Sarah Hunter noted on Tuesday that the Aussie dollar has been behaving differently against the greenback than what we would historically expect. 'When the outlook for global growth weakens, the Australian dollar typically depreciates,' she explained in a speech at the Economic Society of Australia Business Lunch in Brisbane. This is because investors expect the Australian economy 'to be buffeted by the global headwinds and the RBA to respond with cuts to the cash rate'. The fact that the Australian dollar is a 'risk-sensitive' currency also contributes to the depreciation as 'when global investors are worried, they tend to focus on reducing risk exposure, moving their capital to low-risk assets in countries like the United States, Switzerland and Japan.' 'This means the Australian dollar tends to lose value against these currencies,' she said. When Trump announced his global 'Liberation Day' tariffs the Aussie dollar did as expected and fell, plummeting to below 60 US cents for the first time since the pandemic. However in recent weeks, the Aussie has recovered against the greenback and has been sitting between 64 and 65 US cents which, according to Dr Hunter, is 'more unusual' in a continuing time of uncertainty. Dr Hunter said this is in part due to a broad weakness in the USD after some global investors reduced their exposure to US assets. 'The weakness in the US dollar during a period of heightened risk is in contrast with many previous episodes,' she said, 'though it's too early to know whether this dynamic will continue.'
